A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7442 in Healthy Japanese Participants
Latest Information Update: 29 Jun 2022
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 24 Jun 2022 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Planned End Date changed from 4 Jul 2022 to 14 Jun 2022.
- 13 Dec 2021 Planned primary completion date changed from 4 Jul 2022 to 14 Jun 2022.